Dr. Josep Bassaganya-Riera and affiliated entities

NImmune Biotherapeutics is a clinical-stage biotechnology company founded by Dr. Josep Bassaganya-Riera that specializes in developing precision medicines for autoimmune and inflammatory diseases. The company utilizes its proprietary TITAN informatics platform, which integrates advanced computational modeling with experimental validation to discover novel therapeutic targets and candidates. NImmune's pipeline is centered on oral, small-molecule agonists of the LANCL2 and PLXDC2 pathways, designed to provide potent anti-inflammatory effects with a favorable safety profile. Its lead candidate, NIM-1324, is currently in Phase 2 development for the treatment of Ulcerative Colitis and Crohn's Disease. The company aims to transform the treatment landscape for immunology by leveraging biomarker-driven patient stratification to ensure the right patients receive the most effective therapies. NImmune represents the latest venture from the team that previously founded Landos Biopharma, continuing their focus on innovative small-molecule solutions for chronic inflammation.